Vaccine Reaction
77
3
9
34
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 77 trials
100.0%
+13.5% vs benchmark
36%
28 trials in Phase 3/4
6%
2 of 34 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 34 completed trials
Clinical Trials (77)
R21/MM Dosing, Presentations, and Preservatives
Understanding Poor Vaccine Responses to Hepatitis B Vaccination
Intradermal Influenza Vaccination
Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax Adjuvant
Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants
Myocardial Injury and Dysfunction Associated With COVID-19 Vaccination
Optimal Timing of Hepatitis B Vaccination After Transplants
Infant Pain During Vaccination and Maternal Anxiety
Modification of the COVID-19 Vaccine Response by an Intervention on the Intestinal Flora
Long COVID and Its Associations With Health Outcomes in Older Adults
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants
Allergy and COVID-19 Vaccines
Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
B. Infantis Supplementation to Improve Immunity in Infants Exposed to HIV
Study on New Strategies for Hepatitis B Virus Immunization
Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection
Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System